We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age (GRC28)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 20, 2005
Last Update Posted: January 28, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Sanofi Pasteur, a Sanofi Company
Information provided by:
Seattle Children's Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2007
  Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Englund JA, Walter EB, Black S, et al. Safety and Immunogenicity of Fluzone Trivalent Inactivated Influenza Vaccine (TIV) in Infants 6-12 Weeks of Age. Presented at Infectious Disease Society of America (IDSA), Toronto, Oct. 14, 2006